Fluorine in PDB 8pmo: Crystal Structure of Human V122I Transthyretin in Complex with Pitb (Pharmacokinetically Improved Ttr Binder)
Protein crystallography data
The structure of Crystal Structure of Human V122I Transthyretin in Complex with Pitb (Pharmacokinetically Improved Ttr Binder), PDB code: 8pmo
was solved by
N.Varejao,
F.Pinheiro,
I.Pallares,
S.Ventura,
D.Reverter,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Resolution Low / High (Å)
|
66.05 /
1.24
|
Space group
|
P 21 21 2
|
Cell size a, b, c (Å), α, β, γ (°)
|
83.406,
43.782,
66.045,
90,
90,
90
|
R / Rfree (%)
|
19 /
21.2
|
Fluorine Binding Sites:
The binding sites of Fluorine atom in the Crystal Structure of Human V122I Transthyretin in Complex with Pitb (Pharmacokinetically Improved Ttr Binder)
(pdb code 8pmo). This binding sites where shown within
5.0 Angstroms radius around Fluorine atom.
In total 2 binding sites of Fluorine where determined in the
Crystal Structure of Human V122I Transthyretin in Complex with Pitb (Pharmacokinetically Improved Ttr Binder), PDB code: 8pmo:
Jump to Fluorine binding site number:
1;
2;
Fluorine binding site 1 out
of 2 in 8pmo
Go back to
Fluorine Binding Sites List in 8pmo
Fluorine binding site 1 out
of 2 in the Crystal Structure of Human V122I Transthyretin in Complex with Pitb (Pharmacokinetically Improved Ttr Binder)
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 1 of Crystal Structure of Human V122I Transthyretin in Complex with Pitb (Pharmacokinetically Improved Ttr Binder) within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:F201
b:17.7
occ:0.50
|
F05
|
A:ZP2201
|
0.0
|
17.7
|
0.5
|
C04
|
A:ZP2201
|
1.4
|
16.0
|
0.5
|
C03
|
A:ZP2201
|
2.4
|
17.4
|
0.5
|
C06
|
A:ZP2201
|
2.4
|
21.3
|
0.5
|
O
|
A:ALA108
|
3.0
|
20.0
|
1.0
|
C
|
A:ALA108
|
3.1
|
17.9
|
1.0
|
N
|
A:ALA109
|
3.3
|
14.3
|
1.0
|
CB
|
A:ALA108
|
3.4
|
19.8
|
1.0
|
CA
|
A:ALA109
|
3.5
|
14.9
|
1.0
|
N
|
A:LEU110
|
3.5
|
14.1
|
1.0
|
O
|
A:SER117
|
3.6
|
18.6
|
0.3
|
C
|
A:ALA109
|
3.6
|
14.7
|
1.0
|
O
|
A:SER117
|
3.6
|
18.8
|
0.3
|
C02
|
A:ZP2201
|
3.6
|
17.7
|
0.5
|
C07
|
A:ZP2201
|
3.7
|
23.6
|
0.5
|
OG1
|
A:THR119
|
3.8
|
20.6
|
0.4
|
CA
|
A:ALA108
|
3.8
|
16.8
|
1.0
|
N
|
A:THR119
|
3.9
|
15.9
|
0.6
|
O
|
A:SER117
|
4.0
|
14.8
|
0.4
|
N
|
A:THR119
|
4.1
|
16.7
|
0.4
|
CB
|
A:LEU110
|
4.1
|
15.4
|
1.0
|
CG2
|
A:THR119
|
4.1
|
19.6
|
0.6
|
C08
|
A:ZP2201
|
4.1
|
22.0
|
0.5
|
CA
|
A:THR118
|
4.2
|
19.5
|
1.0
|
OG
|
A:SER117
|
4.2
|
19.6
|
0.3
|
C
|
A:SER117
|
4.2
|
17.6
|
0.3
|
C
|
A:SER117
|
4.2
|
17.6
|
0.3
|
CB
|
A:THR119
|
4.3
|
19.2
|
0.4
|
O
|
A:ALA109
|
4.3
|
16.2
|
1.0
|
CA
|
A:LEU110
|
4.3
|
13.8
|
1.0
|
C
|
A:SER117
|
4.4
|
17.7
|
0.4
|
C
|
A:THR118
|
4.4
|
18.9
|
1.0
|
N
|
A:THR118
|
4.5
|
19.4
|
1.0
|
CB
|
A:THR119
|
4.7
|
18.1
|
0.6
|
OG
|
A:SER117
|
4.8
|
20.4
|
0.3
|
O01
|
A:ZP2201
|
4.8
|
18.6
|
0.5
|
CA
|
A:THR119
|
4.8
|
15.8
|
0.4
|
N
|
A:ALA108
|
4.8
|
15.9
|
1.0
|
CA
|
A:THR119
|
4.9
|
15.1
|
0.6
|
CB
|
A:SER117
|
4.9
|
19.8
|
0.4
|
CB
|
A:ALA109
|
5.0
|
16.5
|
1.0
|
C09
|
A:ZP2201
|
5.0
|
34.0
|
0.5
|
|
Fluorine binding site 2 out
of 2 in 8pmo
Go back to
Fluorine Binding Sites List in 8pmo
Fluorine binding site 2 out
of 2 in the Crystal Structure of Human V122I Transthyretin in Complex with Pitb (Pharmacokinetically Improved Ttr Binder)
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 2 of Crystal Structure of Human V122I Transthyretin in Complex with Pitb (Pharmacokinetically Improved Ttr Binder) within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
B:F201
b:18.9
occ:0.48
|
F05
|
B:ZP2201
|
0.0
|
18.9
|
0.5
|
C04
|
B:ZP2201
|
1.3
|
20.1
|
0.5
|
C03
|
B:ZP2201
|
2.3
|
17.1
|
0.5
|
C06
|
B:ZP2201
|
2.4
|
21.9
|
0.5
|
O
|
B:ALA108
|
2.8
|
17.9
|
1.0
|
C
|
B:ALA108
|
2.9
|
16.0
|
1.0
|
N
|
B:ALA109
|
3.1
|
14.1
|
1.0
|
O
|
B:SER117
|
3.1
|
17.4
|
0.4
|
O
|
B:SER117
|
3.2
|
17.6
|
0.2
|
CA
|
B:ALA109
|
3.2
|
13.3
|
1.0
|
CB
|
B:ALA108
|
3.3
|
18.5
|
1.0
|
C
|
B:ALA109
|
3.4
|
14.2
|
1.0
|
N
|
B:LEU110
|
3.5
|
13.4
|
1.0
|
O
|
B:SER117
|
3.6
|
15.6
|
0.4
|
C02
|
B:ZP2201
|
3.6
|
17.0
|
0.5
|
C07
|
B:ZP2201
|
3.6
|
23.8
|
0.5
|
N
|
B:THR119
|
3.7
|
16.6
|
0.7
|
CA
|
B:THR118
|
3.7
|
18.1
|
1.0
|
CA
|
B:ALA108
|
3.7
|
15.6
|
1.0
|
N
|
B:THR119
|
3.8
|
17.1
|
0.3
|
OG1
|
B:THR119
|
3.8
|
19.1
|
0.3
|
C
|
B:SER117
|
3.9
|
17.2
|
0.4
|
C
|
B:SER117
|
3.9
|
17.3
|
0.2
|
C
|
B:THR118
|
4.0
|
19.2
|
1.0
|
C
|
B:SER117
|
4.0
|
16.4
|
0.4
|
C08
|
B:ZP2201
|
4.1
|
18.5
|
0.5
|
CG2
|
B:THR119
|
4.1
|
19.6
|
0.7
|
N
|
B:THR118
|
4.2
|
16.9
|
1.0
|
CB
|
B:LEU110
|
4.2
|
16.5
|
1.0
|
O
|
B:ALA109
|
4.2
|
16.3
|
1.0
|
CB
|
B:THR119
|
4.3
|
17.5
|
0.3
|
CA
|
B:LEU110
|
4.4
|
14.4
|
1.0
|
OG
|
B:SER117
|
4.6
|
19.0
|
0.2
|
CB
|
B:THR119
|
4.6
|
17.7
|
0.7
|
CA
|
B:THR119
|
4.7
|
15.8
|
0.3
|
CA
|
B:THR119
|
4.7
|
14.3
|
0.7
|
N
|
B:ALA108
|
4.7
|
15.3
|
1.0
|
CB
|
B:ALA109
|
4.7
|
16.0
|
1.0
|
O01
|
B:ZP2201
|
4.7
|
26.1
|
0.5
|
OG
|
B:SER117
|
4.8
|
18.5
|
0.4
|
CB
|
B:THR118
|
4.9
|
18.2
|
1.0
|
C09
|
B:ZP2201
|
4.9
|
28.4
|
0.5
|
CB
|
B:SER117
|
4.9
|
19.4
|
0.4
|
OG1
|
B:THR118
|
4.9
|
18.8
|
1.0
|
O
|
B:THR119
|
5.0
|
17.7
|
0.7
|
O
|
B:THR118
|
5.0
|
19.4
|
1.0
|
|
Reference:
F.Pinheiro,
N.Varejao,
A.Sanchez-Morales,
F.Bezerra,
S.Navarro,
A.Velazquez-Campoy,
F.Busque,
M.R.Almeida,
R.Alibes,
D.Reverter,
I.Pallares,
S.Ventura.
Pitb: A High Affinity Transthyretin Aggregation Inhibitor with Optimal Pharmacokinetic Properties. Eur.J.Med.Chem. V. 261 15837 2023.
ISSN: ISSN 0223-5234
PubMed: 37837673
DOI: 10.1016/J.EJMECH.2023.115837
Page generated: Fri Aug 2 22:18:26 2024
|